Evaxion Biotech AS - ADR

NEW
NAS:EVAX (Denmark)   ADR
$ 1.88 -0.020 (-1.05%) 10:54 AM EST
At Loss
P/B:
31.33
Market Cap:
$ 11.78M
Enterprise V:
$ 14.65M
Volume:
53.49K
Avg Vol (2M):
3.64M
Warning! GuruFocus detected 3 Severe warning signs with EVAX. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
53.49K
Market Cap $:
11.78M
At Loss
Avg Vol (2M):
3.64M
Enterprise Value $:
14.65M
PB Ratio:
31.33
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Evaxion Biotech AS

ISIN : US29970R2040
https://www.evaxion-biotech.com
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Share Class Description:

EVAX: ADR
Compare
Compare
SLGLERNASYBXMRKRGOVXTRAWNEUPABVCNRXSOCEAVRTXASX:CSLREGNXKRX:207940XBRU:ARGXXBRU:UCBALNYONCBNTXXKRX:068270
Traded in other countries / regions
EVAX.USA
IPO Date
2021-02-05
Description
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Financial Strength

2/10
Name Current Vs Industry Vs History
Cash-To-Debt 0.44
Equity-to-Asset 0.01
Debt-to-Equity 141.74
Debt-to-EBITDA -0.94
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -11.98
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 8.3
3-Year EPS without NRI Growth Rate 4.4
3-Year FCF Growth Rate 6.4
Future 3-5Y Total Revenue Growth Rate Estimate 438.98

Momentum Rank

3/10
Name Current Vs Industry Vs History
5-Day RSI 25.94
9-Day RSI 34.19
14-Day RSI 37.22
3-1 Month Momentum % -70.42
6-1 Month Momentum % -83.9
12-1 Month Momentum % -86.36

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -32.8
Shareholder Yield % -2.57

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -457.42
Net Margin % -347.86
FCF Margin % -539.54
ROA % -73.57
ROIC % -158.45
3-Year ROIIC % -99.12
ROC (Joel Greenblatt) % -261.58
ROCE % -83.48

GF Value Rank

Name Current Vs Industry Vs History
Forward PE Ratio 0.51
PS Ratio 0.6
PB Ratio 31.33
Price-to-Tangible-Book 31.33
EV-to-EBIT -1.31
EV-to-EBITDA -1.31
EV-to-Revenue 4.45
EV-to-Forward-Revenue 1.21
EV-to-FCF -0.81
Earnings Yield (Greenblatt) % -76.34
FCF Yield % -150.88

Financials (Next Earnings Date:2025-03-27 Est.)

EVAX's 30-Y Financials
AAPL
Income Statement Breakdown FY
Not Enough Data
AAPL
Balance Sheet Breakdown
Not Enough Data
AAPL
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:EVAX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Evaxion Biotech AS Executives

Details

GF Value

EVAX

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3.295
EPS (TTM) ($) -14
Beta -0.28
3-Year Sharpe Ratio -1.34
3-Year Sortino Ratio -1.52
Volatility % 77.79
14-Day RSI 37.22
14-Day ATR ($) 0.518825
20-Day SMA ($) 2.56775
12-1 Month Momentum % -86.36
52-Week Range ($) 1.78 - 22.0475
Shares Outstanding (Mil) 6.27

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Evaxion Biotech AS Filings

Filing Date Document Date Form
No Filing Data

Evaxion Biotech AS Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Evaxion Biotech AS Frequently Asked Questions

What is Evaxion Biotech AS(EVAX)'s stock price today?
The current price of EVAX is $1.88. The 52 week high of EVAX is $22.05 and 52 week low is $1.78.
When is next earnings date of Evaxion Biotech AS(EVAX)?
The next earnings date of Evaxion Biotech AS(EVAX) is 2025-03-27 Est..
Does Evaxion Biotech AS(EVAX) pay dividends? If so, how much?
Evaxion Biotech AS(EVAX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.